Cannabinoids and Mental Health, Part 2 : The Search for Clinical Applications

Copyright 2019, SLACK Incorporated..

Patients with psychiatric conditions are increasingly using cannabinoids, particularly cannabidiol (CBD), to treat their own symptoms. After reviewing the mechanism of action of CBD, the current article examines the existing evidence for CBD in the treatment of schizophrenia, anxiety, autism, posttraumatic stress disorder, and insomnia, and discusses the challenges in translating these studies, often using very high doses of CBD, into clinical practice. Until additional, well-designed studies that examine the more common practice of lower doses of CBD are performed, a harm-reduction, patient-centered, empiric approach is encouraged to optimize symptom reduction while at the same time avoiding the known risks of cannabis. [Journal of Psychosocial Nursing and Mental Health Services, 57(10), 7-11.].

Medienart:

E-Artikel

Erscheinungsjahr:

2019

Erschienen:

2019

Enthalten in:

Zur Gesamtaufnahme - volume:57

Enthalten in:

Journal of psychosocial nursing and mental health services - 57(2019), 10 vom: 01. Okt., Seite 7-11

Sprache:

Englisch

Beteiligte Personen:

Penn, Andrew [VerfasserIn]

Links:

Volltext

Themen:

19GBJ60SN5
Cannabidiol
Journal Article

Anmerkungen:

Date Completed 09.03.2020

Date Revised 09.03.2020

published: Print

Citation Status MEDLINE

doi:

10.3928/02793695-20190919-02

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM301810982